Use of abatacept in rheumatoid arthritis.

Details

Ressource 1Download: 22581564.pdf (638.97 [Ko])
State: Serval
Version: Final published version
Serval ID
serval:BIB_33D246307EC1
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Use of abatacept in rheumatoid arthritis.
Journal
Swiss medical weekly
Author(s)
von Kempis J., Dudler J., Hasler P., Kyburz D., Tyndall A., Zufferey P., Villiger P.M.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
11/05/2012
Peer-reviewed
Oui
Volume
142
Pages
w13581
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: epublish
Abstract
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.

Keywords
Abatacept, Antirheumatic Agents/adverse effects, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/diagnostic imaging, Arthritis, Rheumatoid/drug therapy, Humans, Immunoconjugates/adverse effects, Immunoconjugates/therapeutic use, Methotrexate/therapeutic use, Radiography, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Web of science
Open Access
Yes
Create date
10/01/2013 17:50
Last modification date
08/05/2019 16:51
Usage data